Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Ask to Join

BeOne Study ID

BG-C9074-101

ClinicalTrials.gov ID

NCT06233942

EudraCT Number

2023-509958-65-00

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents